Licensed use — if any
No authorised human therapeutic indication is established. FDA's 2026 review covered nominated KPV bulk substances for wound-healing and inflammatory conditions.
Preview openPlanned full launch in
--Days--Hrs--Min--Sec
← Peptide Intelligence
Alpha-MSH-derived tripeptide fragment
KPV
Lys-Pro-Val
A three-amino-acid fragment associated with alpha-melanocyte-stimulating hormone research and promoted for inflammatory and wound-healing uses.
Research interest
Preclinical inflammatory signalling, epithelial biology and wound-healing models.
Evidence lens
Known does not mean proven for everything.
The strongest claim on the page should never be stronger than the strongest source behind it.
- The mechanistic and animal literature creates hypotheses, not a proven human treatment.
- FDA reported that it had not identified human exposure data for KPV drug products.
- The proposed human safety profile is therefore not established.
- Human pharmacokinetics and clinically meaningful efficacy.
- Long-term toxicity and immunogenicity.
- Safe formulation, route and interaction profile.
- FDA says important human safety information is missing.
- Peptide identity and impurity risks remain when material is not regulated.
- Inflammatory symptoms can signal conditions requiring diagnosis rather than self-treatment.
Regulatory snapshot
Jurisdiction and context matter.
Not presented as a UK-authorised medicine. Verify classification and claims with MHRA advice.
Not FDA approved; reviewed by FDA in 2026 as a nominated compounding bulk substance.
Athletes should verify current WADA and Global DRO status; unapproved status can itself be relevant under S0.
Primary sources
Open the record.
Statuses change. Always check the current regulator, product label, trial record and anti-doping list.
Do not start, stop or source a medicine based on this page. Speak to a qualified healthcare professional and use regulated supply routes. Call 999 in an emergency or NHS 111 for urgent advice.
Continue through the library →